Recipharm AB publishes its interim report January - September 2019
July – September 2019 · Net sales amounted to SEK 1,797 million (1,421), an increase of 26% · EBITDA increased by 87% and amounted to SEK 282 million (151) corresponding to an EBITDA margin of 15.7% (10,6) · Operating profit (EBIT) amounted to SEK 95 million (25) · Profit after tax amounted to SEK 81 million (-9) corresponding to a net margin of 4.5% (-0.6) · Earnings per share amounted to SEK 1.19 (-0.13) before dilution and SEK 1.19 (-0.13) after dilution January – September 2019 · Net sales amounted to SEK 5,476 million (4,635), an increase of 18% · EBITDA